GoodRx Holdings (GDRX) Research & Development (2019 - 2026)

GoodRx Holdings (GDRX) has 8 years of Research & Development data on file, last reported at $30.2 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 3.1% year-over-year to $30.2 million; the trailing twelve-month figure through Mar 2026 stood at $172.6 million (up 3219.5% YoY), and the FY2025 full-year result was $121.0 million, down 2.2% from the prior year.
• Research & Development climbed to $30.2 million in Q1 2026, from $28.9 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $94.3 million in Q2 2022 to a low of -$149.5 million in Q4 2024.
• A 5-year average of $47.6 million and a median of $35.9 million in 2022 frame the typical range for Research & Development.
• Across the five-year window, Research & Development jumped 255.31% in 2022 and tumbled 566.83% in 2024, its largest moves.
• Tracing GDRX's Research & Development over 5 years: stood at $84.1 million in 2022, then sank by 61.92% to $32.0 million in 2023, then plunged by 566.83% to -$149.5 million in 2024, then soared by 119.35% to $28.9 million in 2025, then grew by 4.28% to $30.2 million in 2026.
• Business Quant data shows GDRX's Research & Development at $30.2 million in Q1 2026, $28.9 million in Q4 2025, and $83.5 million in Q3 2025.